Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.

Busby J, Holweg CTJ, Chai A, Bradding P, Cai F, Chaudhuri R, Mansur AH, Lordan JL, Matthews JG, Menzies-Gow A, Niven R, Staton T, Heaney LG.

Thorax. 2019 Aug;74(8):806-809. doi: 10.1136/thoraxjnl-2018-212709. Epub 2019 Apr 2.

PMID:
30940770
2.

Clarification of epicutaneous immunotherapy trial phase 3 results and methods for qualitative survey design.

Matthews JG, Zawadzki R, Haselkorn T, Rosén K.

Ann Allergy Asthma Immunol. 2018 Nov;121(5):641-642. doi: 10.1016/j.anai.2018.07.045. No abstract available.

PMID:
30389085
3.

Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.

Semprini R, Shortt N, Ebmeier S, Semprini A, Varughese R, Holweg CTJ, Matthews JG, Fingleton J, Weatherall M, Beasley R, Braithwaite I.

Thorax. 2019 Jan;74(1):95-98. doi: 10.1136/thoraxjnl-2018-211657. Epub 2018 Jul 18.

PMID:
30021810
4.

U-BIOPRED: evaluation of the value of a public-private partnership to industry.

Riley JH, Erpenbeck VJ, Matthews JG, Holweg CTJ, Compton C, Seibold W, Higenbottam T, Wagers S, Rowe A, Myles D; Industry Representatives of the U-BIOPRED Study Group.

Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21. Review.

PMID:
29936248
5.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.

Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13.

6.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

7.

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

Zhu R, Zheng Y, Dirks NL, Vadhavkar S, Jin JY, Peng K, Holweg CTJ, Olsson J, Matthews JG, Putnam WS.

Pulm Pharmacol Ther. 2017 Oct;46:88-98. doi: 10.1016/j.pupt.2017.08.010. Epub 2017 Aug 24.

8.

Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.

Staton TL, Arron JR, Olsson J, Holweg CTJ, Matthews JG, Choy DF.

J Allergy Clin Immunol. 2017 May;139(5):1682-1684.e3. doi: 10.1016/j.jaci.2017.01.028. Epub 2017 Feb 24. No abstract available.

PMID:
28238745
9.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.

Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.

PMID:
27616196
10.

Serum periostin is associated with type 2 immunity in severe asthma.

Johansson MW, Evans MD, Crisafi GM, Holweg CTJ, Matthews JG, Jarjour NN.

J Allergy Clin Immunol. 2016 Jun;137(6):1904-1907.e2. doi: 10.1016/j.jaci.2015.12.1346. Epub 2016 Apr 6. No abstract available.

11.

Roles of Periostin in Respiratory Disorders.

Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG, Arron JR.

Am J Respir Crit Care Med. 2016 May 1;193(9):949-56. doi: 10.1164/rccm.201510-2032PP. Review.

12.

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.

Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, Pandis I, Bansal AT, Bel EH, Auffray C, Compton CH, Bisgaard H, Bucchioni E, Caruso M, Chanez P, Dahlén B, Dahlen SE, Dyson K, Frey U, Geiser T, Gerhardsson de Verdier M, Gibeon D, Guo YK, Hashimoto S, Hedlin G, Jeyasingham E, Hekking PP, Higenbottam T, Horváth I, Knox AJ, Krug N, Erpenbeck VJ, Larsson LX, Lazarinis N, Matthews JG, Middelveld R, Montuschi P, Musial J, Myles D, Pahus L, Sandström T, Seibold W, Singer F, Strandberg K, Vestbo J, Vissing N, von Garnier C, Adcock IM, Wagers S, Rowe A, Howarth P, Wagener AH, Djukanovic R, Sterk PJ, Chung KF; U-BIOPRED Study Group.

Eur Respir J. 2015 Nov;46(5):1308-21. doi: 10.1183/13993003.00779-2015. Epub 2015 Sep 10. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

13.

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Catley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T.

Thorax. 2016 Feb;71(2):187-9. doi: 10.1136/thoraxjnl-2015-207326. Epub 2015 Jul 23. Review.

14.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K.

Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.

15.

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM.

Sci Transl Med. 2014 Jul 2;6(243):243ra85. doi: 10.1126/scitranslmed.3008961.

16.

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.

PMID:
24313774
17.

OX40L blockade and allergen-induced airway responses in subjects with mild asthma.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M, Kipling C, Dua B, Mosesova S, Putnam W, Zheng Y, Scheerens H, McClintock D, Matthews JG, O'Byrne PM.

Clin Exp Allergy. 2014 Jan;44(1):29-37. doi: 10.1111/cea.12235.

18.

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.

19.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.

PMID:
23726041
20.

Redefining approaches to asthma: developing targeted biologic therapies.

Arron JR, Scheerens H, Matthews JG.

Adv Pharmacol. 2013;66:1-49. doi: 10.1016/B978-0-12-404717-4.00001-9. Review.

PMID:
23433454
21.

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.

22.

Lebrikizumab treatment in adults with asthma.

Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG.

N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.

23.

The perceived prognosis of endodontic treatment and implant therapy among dental practitioners.

Stockhausen R, Aseltine R Jr, Matthews JG, Kaufman B.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Feb;111(2):e42-7. doi: 10.1016/j.tripleo.2010.10.007.

PMID:
21237427
24.

Unstable hemiarthroplasty of the hip-treated with a simple technique of acetabular augmentation.

Maheshwari R, Kumar PN, Matthews JG.

J Arthroplasty. 2007 Feb;22(2):231-4.

PMID:
17275639
25.

A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN).

Rosivatz E, Matthews JG, McDonald NQ, Mulet X, Ho KK, Lossi N, Schmid AC, Mirabelli M, Pomeranz KM, Erneux C, Lam EW, Vilar R, Woscholski R.

ACS Chem Biol. 2006 Dec 15;1(12):780-90.

PMID:
17240976
26.

Expression of nonmuscle cofilin-1 and steroid responsiveness in severe asthma.

Vasavda N, Eichholtz T, Takahashi A, Affleck K, Matthews JG, Barnes PJ, Adcock IM.

J Allergy Clin Immunol. 2006 Nov;118(5):1090-6. Epub 2006 Sep 25.

PMID:
17088134
27.

Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients.

Matthews JG, Ito K, Barnes PJ, Adcock IM.

J Allergy Clin Immunol. 2004 Jun;113(6):1100-8.

PMID:
15208591
28.

p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma.

Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM.

J Allergy Clin Immunol. 2002 Apr;109(4):649-57.

PMID:
11941315
29.

Aspirin-related small bowel diaphragm disease identified during emergency laparotomy.

Crowther SM, Matthews JG.

Ulster Med J. 2000 Nov;69(2):175-6. No abstract available.

30.

High tibial osteotomy without internal fixation for medial unicompartmental osteoarthrosis.

Khan MT, Matthews JG.

Orthopedics. 2000 Oct;23(10):1045-8.

PMID:
11045550
31.

In memory of Granny

Matthews JG.

Nursing. 1999 Apr;29(4):76. No abstract available.

PMID:
10578858
32.

Docking of puppies' tails.

Matthews JG.

Vet Rec. 1995 Sep 30;137(14):356. No abstract available.

PMID:
8560693
33.

Fading characteristics of a 2.3 GHz radio telemetry channel in a hospital building.

Wang LQ, Evans NE, Burns JB, Matthews JG.

Med Eng Phys. 1995 Apr;17(3):226-31.

PMID:
7795861
34.

Pneumonia in patients with multiple trauma.

McRitchie DI, Matthews JG, Fink MP.

Clin Chest Med. 1995 Mar;16(1):135-46. Review.

PMID:
7768087
35.

Relationships between pHi and tension in isolated rat mesenteric resistance arteries.

Matthews JG, Graves JE, Poston L.

J Vasc Res. 1992 Jul-Aug;29(4):330-40.

PMID:
1327245
36.

Clinical observations on four cases of scrapie in goats.

Andrews AH, Laven R, Matthews JG.

Vet Rec. 1992 Feb 1;130(5):101. No abstract available.

PMID:
1557871
37.

Improving care: a study of orthopaedic outpatient referrals.

Roland MO, Porter RW, Matthews JG, Redden JF, Simonds GW, Bewley B.

BMJ. 1991 May 11;302(6785):1124-8.

38.

Condensing osteitis of the clavicle: a rare but frequently misdiagnosed condition.

Greenspan A, Gerscovich E, Szabo RM, Matthews JG 2nd.

AJR Am J Roentgenol. 1991 May;156(5):1011-5. Review.

PMID:
2017922
39.

Osteoarthritis of the fabella: a fourth knee compartment?

Clarke AM, Matthews JG.

J R Coll Surg Edinb. 1991 Feb;36(1):58. No abstract available.

PMID:
2038004
40.

Endoprosthetic reconstruction after bone tumor resections of the proximal tibia.

Eckardt JJ, Matthews JG 2nd, Eilber FR.

Orthop Clin North Am. 1991 Jan;22(1):149-60.

PMID:
1992431
41.

Commitment patients in a private psychiatric hospital: a pilot program in Tennessee.

Urrutia G, Morrissey JA, Matthews JG.

Psychiatr Hosp. 1987 Summer;18(3):115-9.

PMID:
10318069
42.

Experimental study in rat metatarsals to determine whether callus vascularity is an indicator of the mechanical strength of healing fractures.

Powell ES, Lake DN, Matthews JG, Lawford PV, Duckworth T, Black MM.

J Biomed Eng. 1987 Jul;9(3):249-56.

PMID:
3613548
43.

Ultrastructure and cytogenetics in seven cases of acute promyelocytic leukaemia (APL).

Pearson EC, Matthews JG, Hayhoe FG.

Br J Haematol. 1986 Jun;63(2):247-56.

PMID:
3013272
44.

Analysis of G banded karyotypes in myeloma cells.

Chen KC, Bevan PC, Matthews JG.

J Clin Pathol. 1986 Mar;39(3):260-6.

45.

An unusual translocation, t(3;8), and deletion of chromosome 21 in acute myeloid leukemia.

Matthews JG, Swirsky DM, Hayhoe FG.

Cancer Genet Cytogenet. 1984 May;12(1):27-30.

PMID:
6585266
46.

Harvest of human bone marrow directly from bone.

Sharp TG, Sachs DH, Matthews JG, Maples J, Woody JN, Rosenberg SA.

J Immunol Methods. 1984 Apr 27;69(2):187-95.

PMID:
6609206
47.

8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features.

Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JK, Hayhoe FG.

Br J Haematol. 1984 Feb;56(2):199-213.

PMID:
6197988
49.

Biologic fixation of a modified Moore prosthesis. Part I. Evaluation of early clinical results.

Engh CA, Bobyn JD, Matthews JG 2nd.

Hip. 1984:95-110. No abstract available.

PMID:
6526679
50.

Groups of darkly stained chromosomes may be artifacts.

Li YS, Matthews JG, Flemans RJ, Hayhoe FG.

Cancer Genet Cytogenet. 1984 Jan;11(1):37-43.

PMID:
6197158

Supplemental Content

Loading ...
Support Center